Pfizer heralds “paradigm shift” in hemophilia B gene therapy with FDA approval
Pfizer's groundbreaking $3.5 million gene therapy for hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine
Archives for April 30, 2024
Why are nearly half of all recent biotech RNA alliances in Asia-Pacific betting big on oligonucleotides?
A recent study finds RNA deals are “dominated” by oligonucleotides and mRNA vaccines in APAC
Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration
Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively